CD274 and neoplasm: PD-1/PD-L1 is the most successful immune checkpoint target of tumor immunotherapy and its blocking antibodies have been found to exert significant clinic therapeutic effects in various tumors, thus having been widely prescribed by tumor patients (Gajewski and Fessler, 2020).